Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2

Biochemical Pharmacology

Volumn 81, Issue 4, 2011, Pages 510-517

  Huang, Wen Yu ^a   Yang, Pei Ming ^a   Chang, Yu Fan ^a   Marquez, Victor E ^b   Chen, Ching Chow ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

EZH2; HDAC; Methotrexate; p21; p53

Indexed keywords

HISTONE DEACETYLASE; LYSINE; METHOTREXATE; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SERINE; TRANSCRIPTION FACTOR EZH2; UVOMORULIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

APOPTOSIS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; DOWN-REGULATION; HISTONE DEACETYLASES; HUMANS; METHOTREXATE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78751591177     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.11.014     Document Type: Article

References (53)

1. K.L. DeCicco, T. Tanaka, F. Andreola, and L.M. De Luca The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway Carcinogenesis 25 2004 1805 1812
2. P. Yang, M.S. Allen, M.C. Aubry, J.A. Wampfler, R.S. Marks, and E.S. Edell Clinical features of 5628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003 Chest 128 2005 452 462
3. C. Manegold Chemotherapy for advanced non-small cell lung cancer: standards Lung Cancer (Amsterdam, Netherlands) 34 Suppl. 2 2001 S165 S170
4. Y. Haupt, R. Maya, A. Kazaz, and M. Oren Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299
5. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat Rev Cancer 2 2002 594 604
6. A.M. Bode, and Z. Dong Post-translational modification of p53 in tumorigenesis Nat Rev Cancer 4 2004 793 805
7. A. Ito, C.H. Lai, X. Zhao, S. Saito, M.H. Hamilton, and E. Appella p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2 EMBO J 20 2001 1331 1340
8. W. Gu, X.L. Shi, and R.G. Roeder Synergistic activation of transcription by CBP and p53 Nature 387 1997 819 823
9. C.G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, and S.A. Tomlins EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci USA 100 2003 11606 11611
10. S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, and M.G. Sanda The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
11. F.M. Raaphorst, C.J. Meijer, E. Fieret, T. Blokzijl, E. Mommers, and H. Buerger Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene Neoplasia 5 2003 481 488
12. R.H. Breuer, P.J. Snijders, E.F. Smit, T.G. Sutedja, R.G. Sewalt, and A.P. Otte Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis Neoplasia 6 2004 736 743
13. J. van der Vlag, and A.P. Otte Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation Nat Genet 23 1999 474 478
14. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 2006 769 784
15. P.A. Croonquist, and B. Van Ness The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype Oncogene 24 2005 6269 6280
16. J. Tan, X. Yang, L. Zhuang, X. Jiang, W. Chen, and P.L. Lee Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells Genes Dev 21 2007 1050 1063
17. C.H. Damsky, J. Richa, D. Solter, K. Knudsen, and C.A. Buck Identification and purification of a cell surface glycoprotein mediating intercellular adhesion in embryonic and adult tissue Cell 34 1983 455 466
18. R. Moll, M. Mitze, U.H. Frixen, and W. Birchmeier Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas Am J Pathol 143 1993 1731 1742
19. H. Oka, H. Shiozaki, K. Kobayashi, M. Inoue, H. Tahara, and T. Kobayashi Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis Cancer Res 53 1993 1696 1701
20. Q. Cao, J. Yu, S.M. Dhanasekaran, J.H. Kim, R.S. Mani, and S.A. Tomlins Repression of E-cadherin by the polycomb group protein EZH2 in cancer Oncogene 27 2008 7274 7284
21. Y.L. Chao, C.R. Shepard, and A. Wells Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition Mol Cancer 9 2010 179
22. E.A. Olsen The pharmacology of methotrexate J Am Acad Dermatol 25 1991 306 318
23. A. Lorico, G. Toffoli, M. Boiocchi, E. Erba, M. Broggini, and G. Rappa Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid Cancer Res 48 1988 2036 2041
24. A. Villunger, E.M. Michalak, L. Coultas, F. Mullauer, G. Bock, and M.J. Ausserlechner p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa Science 302 2003 1036 1038
25. L.J. Juan, W.J. Shia, M.H. Chen, W.M. Yang, E. Seto, and Y.S. Lin Histone deacetylases specifically down-regulate p53-dependent gene activation J Biol Chem 275 2000 20436 20443
26. A. Ito, Y. Kawaguchi, C.H. Lai, J.J. Kovacs, Y. Higashimoto, and E. Appella MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation EMBO J 21 2002 6236 6245
27. P.M. Yang, J.H. Lin, W.Y. Huang, Y.C. Lin, S.H. Yeh, and C.C. Chen Inhibition of histone deacetylase activity is a novel function of antifolate drug methotrexate Biochem Biophys Res Commun 391 2010 1396 1399
28. W. Fiskus, M. Pranpat, M. Balasis, B. Herger, R. Rao, and A. Chinnaiyan Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells Mol Cancer Ther 5 2006 3096 3104
29. F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, and G. Sinaccio Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature Oncologist 12 2007 451 464
30. M.A. Glozak, and E. Seto Histone deacetylases and cancer Oncogene 26 2007 5420 5432
31. M. Li, J. Luo, C.L. Brooks, and W. Gu Acetylation of p53 inhibits its ubiquitination by Mdm2 J Biol Chem 277 2002 50607 50611
32. E. Appella, and C.W. Anderson Post-translational modifications and activation of p53 by genotoxic stresses Eur J Biochem 268 2001 2764 2772
33. C. Blattner, E. Tobiasch, M. Litfen, H.J. Rahmsdorf, and P. Herrlich DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation Oncogene 18 1999 1723 1732
34. T. Thomson, C. Tovar, H. Yang, D. Carvajal, B.T. Vu, and Q. Xu Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis J Biol Chem 279 2004 53015 53022
35. Y. Tang, W. Zhao, Y. Chen, Y. Zhao, and W. Gu Acetylation is indispensable for p53 activation Cell 133 2008 612 626
36. A. Inga, F. Storici, T.A. Darden, and M.A. Resnick Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence Mol Cell Biol 22 2002 8612 8625
37. C.D. Knights, J. Catania, S. Di Giovanni, S. Muratoglu, R. Perez, and A. Swartzbeck Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate J Cell Biol 173 2006 533 544
38. Y. Zhao, S. Lu, L. Wu, G. Chai, H. Wang, and Y. Chen Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1) Mol Cell Biol 26 2006 2782 2790
39. P. May, and E. May Twenty years of p53 research: structural and functional aspects of the p53 protein Oncogene 18 1999 7621 7636
40. T. Waldman, K.W. Kinzler, and B. Vogelstein p21 is necessary for the p53-mediated G1 arrest in human cancer cells Cancer Res 55 1995 5187 5190
41. F. Bunz, A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, and J.P. Brown Requirement for p53 and p21 to sustain G2 arrest after DNA damage Science 282 1998 1497 1501
42. H. Lincet, L. Poulain, J.S. Remy, E. Deslandes, F. Duigou, and P. Gauduchon The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells Cancer Lett 161 2000 17 26
43. L. Qiao, R. McKinstry, S. Gupta, D. Gilfor, J.J. Windle, and P.B. Hylemon Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53 Hepatology 36 2002 39 48
44. K.H. Kang, W.H. Kim, and K.H. Choi p21 promotes ceramide-induced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells Exp Cell Res 253 1999 403 412
45. S.L. Harris, and A.J. Levine The p53 pathway: positive and negative feedback loops Oncogene 24 2005 2899 2908
46. Q. Fei, H. Zhang, X. Chen, J.C. Wang, R. Zhang, and W. Xu Defected expression of E-cadherin in non-small cell lung cancer Lung Cancer (Amsterdam, Netherlands) 37 2002 147 152 (Pubitemid 34831806)
47. R.M. Bremnes, R. Veve, F.R. Hirsch, and W.A. Franklin The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis Lung Cancer (Amsterdam, Netherlands) 36 2002 115 124
48. S.E. Witta, R.M. Gemmill, F.R. Hirsch, C.D. Coldren, K. Hedman, and L. Ravdel Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines Cancer Res 66 2006 944 950
49. K. Yoshiura, Y. Kanai, A. Ochiai, Y. Shimoyama, T. Sugimura, and S. Hirohashi Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas Proc Natl Acad Sci USA 92 1995 7416 7419
50. J.R. Graff, J.G. Herman, R.G. Lapidus, H. Chopra, R. Xu, and D.F. Jarrard E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas Cancer Res 55 1995 5195 5199
51. T. Lin, A. Ponn, X. Hu, B.K. Law, and J. Lu Requirement of the histone demethylase LSD1 in Snai1-mediated transcriptional repression during epithelial-mesenchymal transition Oncogene 2010
52. H. Peinado, E. Ballestar, M. Esteller, and A. Cano Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex Mol Cell Biol 24 2004 306 319
53. E. Sanchez-Tillo, A. Lazaro, R. Torrent, M. Cuatrecasas, E.C. Vaquero, and A. Castells ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1 Oncogene 29 2010 3490 3500